BSG and hepatocellular carcinoma: In our laboratory, we developed the specific mAb (monoclonal antibody) HAb18 against CD147 for use as animmunotherapeuticagent, which has been demonstrated to be safe and efficacious for thetargeted treatment of HCC in clinicalpractice42.